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inclusion of the symptoms. The heterogeneity in defining hypoglycaemia makes 
it difficult to compare the safety of interventions for their drug-induced hypogly-
caemia.
Diabetes/enDocrine DisorDers – cost studies
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Objectives: To estimate the incremental budget impact of the reimbursement 
of long-acting insulin analogues (LAIA) for type 1 diabetes patients (T1DM) in 
Brazil. MethOds: A budget impact analysis (BIA) of LAIA in the Brazilian 
public health system compared to NPH human insulin was performed. The 
analysis’ time horizon was 5 years. The target population used the methodology 
of epidemiological demand, considering estimates of the International Diabetes 
Federation: 11.6 million diabetics of 20-79 years old x 5% T1DM plus 31100 chil-
dren and 10845 adolescents. It considered the incidence of 10.4/100,000 persons 
per year and mortality 23.15/1000 adults per year. The overall mean insulin dose 
was obtained from trials. For the human insulin, we considered the values of last 
purchase of the Ministry of Health. For both insulins, we got the average maxi-
mum sale price for government from CMED list. Then the bargaining power was 
calculated dividing the NPH’s maximum sale price by the Ministry’s purchase 
price, and we applied 50% of the bargaining power to the LAIA’s price. Market 
share was 50%, 60%, 70%, 80% and 80%. Results: The incremental budget 
impact of LAIA would be $93 million in the 1st year, considering 50% of target 
population, and reaching approximately $432 million for 80% of patients. In 5 
years, the calculated budget impact was $617 million. The sensitivity analysis 
indicates the prevalence and analogues prices as villains. cOnclusiOns: LAIA 
are available in Brazil since 2002, although to this day the public health system 
does not make it available to citizens. We can suggest that the reason for non-
coverage is the considerable budget impact, nevertheless our analysis, more com-
plex and with rational methodology, have shown less impact than the analysis 
used in the Ministry’s decision, which BIA was U$ 816 million for the coverage 
of LAIA.
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Objectives: Hypoglycemia is an acute complication of diabetes that increases 
the morbidity, mortality and disease costs. We aimed to estimate the annual NHS 
expenditure managing severe hypoglycemia episodes in type 2 diabetic patients 
in Portugal. MethOds: HIPOS-ER (Hypoglycemia in Portugal Observational Study 
– Emergency Room) study was an observational, cross-sectional, multicenter, 
hospital-based study conducted in seven centers of Portugal mainland within a 
period of 12 months (January 2013 - January 2014). Patient level data were used 
to quantify healthcare resource consumption related to emergency transporta-
tion, emergency department care and hospitalization. Unit costs for 2014 were 
extracted from official sources and reported in euros. Results: A total of 425,706 
admissions at the emergency room were registered in the participating hospitals 
within the shifts covered by HIPOS-ER study. Of these, 0.074% had diabetes type 2 
and were admitted due to an episode of hypoglycemia meaning that theoretically 
2.317 emergencies occur yearly in Portugal due to severe hypoglycemia in Type 
2 diabetic patients (out of an universe of 3.131.126 annual general emergencies 
in Portugal). Considering the HIPOS-ER estimated mean cost for managing this 
type of hypoglycemia (i.e. € 1,479), we expect that around 3.4 millions of euros 
per year are spent in treating this diabetes related complication at emergency 
rooms of NHS Portuguese hospitals. cOnclusiOns: Our estimation highlights 
the potential overall economic burden of severe hypoglycemias in Portugal, mean-
ing that this diabetes-related event must be taken in consideration by different 
healthcare stakeholders not only from strict clinical point of view, but also from 
and economic one. We conclude that severe hypoglycemic events represent a sub-
stantial cost for society and in particular for the hospitals of the National Health 
Service.
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Objectives: Background: The DPP4 inhibitors are among the newer, yet more estab-
lished, classes of diabetes medications. In the US these include: sitagliptin, saxa-
gliptin, linagliptin, and alogliptin. OBJECTIVE: The objective was to compare direct 
medical costs for patients taking DPP4-inhibitors. MethOds: Claims were extracted 
for Humana Medicare or Commercial plan members with > = 1 prescription filled 
for a DPP4-inhibitor between July 1, 2011 and March 31, 2013. The first prescription 
claim for a DPP4 established the index date and index medication, and 12-month 
pre- and post-index data were analyzed. The Diabetes Complications Severity Index 
(DCSI) assessed diabetes-related co-morbidities. Post-index costs (in 2013 US dol-
lars) were compared adjusting for pre-index costs, DCSI, pre-index insulin, age and 
gender using GLMs and p < 0.05. Results: Few patients were prescribed alogliptin. 
The final samples included 22,860 patients with Medicare coverage (17,292 sitagliptin; 
Centre Erfurt/Bad Berka, Erfurt, Germany, 7Clinical Pharmacology, Mannheim/Center for 
Gerontopharmacology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Objectives: The aim of this study was to analyse which factors predict the real-
world macro-/microvascular event, hospitalisation and death risk in patients with 
type 2 diabetes mellitus (T2DM). MethOds: We used a German claims/clinical data 
set (AOK Plus) covering the years 2010-12. Factors associated with event risk were 
analysed by a Kaplan-Meier curve analysis and by multivariable Cox regression mod-
els. Results: 229,042 T2DM patients (mean age 70.2 years; mean CCI 6.03). A total 
of 66.3% of the sample had a mean systolic blood pressure of > 130mmHg (mean: 
135.56mmHg), 48.0% could be considered as obese (BMI> 30). The mean HbA1C in 
the sample was 7.00%; 11.1% of observed patients had a mean HbA1C< 6.0%, 75.3% 
< 7.5%, and 4.5% ≥ 9.0%. The mean observational period per patient from 01/04/2011 
until 31/12/2012 or until first observed all-cause event was 581.9 days (SD: 148.4). 
39,589 patients of the study sample (17.3%) were affected by at least one T2DM-
related event in this period (event frequency per 1,000 patient years: 82.7 macrovas-
cular events; 10.8 microvascular events; 28.4 hospitalisations with T2DM as main 
diagnosis; 40.7 deaths). Among factors that increased the composite event risk were 
patients’ age, male gender, the adapted Charlson-Comorbidity-Index, the adapted 
Diabetes-Complication-Severity Index, previous events, and number of prescribed 
chronic medications. For systolic blood pressure/HbA1C, a double-J/U-curve pattern 
was detected: HbA1C of 6-6.5% and systolic blood pressure of 130-140mmHg were 
associated with the lowest event risk, values below/above that range were associ-
ated with higher risk. However, this pattern was mainly driven by the death risk 
and was much less clearly observed for the macrovascular/microvascular/hospi-
talization risk and for young/less comorbid patients. cOnclusiOns: Both blood 
pressure and HbA1C seem to be very important treatment targets, especially in 
comorbid old patients. Both over- and under-treatment pose a threat to patients 
with type 2 diabetes mellitus.
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Objectives: Patients with type 2 diabetes mellitus (T2DM) display a unique skel-
etal phenotype with either normal or more frequently increased, bone mineral 
density and impaired structural and geometric properties. Alterations in bone 
material properties seem to be the predominant defect leading to increased bone 
fragility. A systematic review and meta-analysis of observational studies is con-
ducted to assess the association between T2DM and fracture risk. MethOds: A 
systematic literature search was performed in Medline and EMBASE databases. 
“Abstracts” from annual scientific meeting of various diabetes and bone and min-
eral societies were also searched to identify relevant studies. Studies reporting 
fracture risk in subjects with T2DM in comparison with subjects without diabetes 
were included. Heterogeneity was calculated by performing I2 statistics. Summary 
relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated 
using random-effects model. Results: Twelve studies met the inclusion criteria 
reporting 25,848 fracture events among 6,12,748 subjects without diabetes (4.2 %) 
and 8570 fracture events among 2,12,011 subjects with T2DM (4.0 %). The pooled 
relative risk (RR) of any fracture in subjects with T2DM was 0.91 (95% CI 0.75 – 1.11, 
p= 0.375). The pooled RR for any fractures in women with T2DM was 0.907 (95% 
CI 0.735- 1.118, 10 studies) compared to subjects without diabetes. The pooled RR 
for any fractures in men with T2DM was 0.868 (95% CI 0.738 to 1.022) compared 
to subjects without diabetes. Sensitivity analysis demonstrated stability of result 
after removing outliers. No publication bias was observed on visual analysis of 
funnel plot. cOnclusiOns: Our meta-analysis suggests that patients of T2DM 
are not at increased risk of incidence of fractures as compared to non diabetic 
subjects.
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Objectives: To examine the heterogeneity in the definitions of hypoglycaemia 
across Randomized Clinical Trials (RCTs) conducted with oral antidiabetic agents 
or insulin. MethOds: RCTs included in the Canadian Agency for Drugs and 
Technologies in Health (CADTH) reports for the second-line and third-line therapy 
for the patients with Type 2 Diabetes were examined. Definitions for overall, major, 
minor, severe, and nocturnal hypoglycaemia were extracted from 76 RCTs. The 
extracted definitions were compared to the definitions of the American Diabetes 
Association (ADA) and European Medicines Agency (EMA). Results: According to 
the ADA and the EMA, hypoglycaemia is defined as an event with a blood glucose 
(BG) ≤ 3.9mmol/L. Only 4 out of 76 studies adhered to the ADA/EMDA definition of 
hypoglycaemia. Generally, hypoglycaemia was defined as a status with BG rang-
ing from < 4 mmol/L to ≤ 2.8mmol/L. Only 17 out of 33 RCTs that defined severe 
hypoglycaemia adhered to the ADA/ EMDA definition. Severe hypoglycaemia was 
defined as a symptomatic condition that required the assistance of a third person 
for resuscitative actions, with or without BG values spanning from < 3.3 mmol/L to 
< 2.0 mmol/L. Major hypoglycaemia was defined as patients being unable to treat 
themselves, with or without a BG value ranging from < 3.1 mmol/L to ≤ 2.8 mmol/L. 
Nocturnal hypoglycaemia was vaguely defined when reported, as episodes occurring 
after evening injection and before breakfast, or between bedtime and morning, or 
any 6 hours or longer interval between 11pm and 8am. cOnclusiOns: Compared 
to the ADA and EMA proposed definitions of hypoglycaemia (BG≤ 3.9mmol/L), the 
studies included in our review had a substantial heterogeneity in their definitions 
of hypoglycaemia not only in terms of the BG values being used, but also with the 
